Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy Volunteers

NCT ID: NCT02249416

Last Updated: 2014-09-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2001-11-30

Brief Summary

The objective of this study was to characterize the effect of two dose combinations of tipranavir/ritonavir (TPV 500 mg/RTV 100 mg and TPV 750 mg/RTV 200 mg) administered twice daily on the pharmacokinetics (PK) of zidovudine (ZDV) and zidovudine-glucuronide (GZDV) as well as the effects of zidovudine on the pharmacokinetics of TPV/RTV

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TPV/RTV low + ZDV

Group Type: EXPERIMENTAL

Tipranavir (TPV) low

Intervention Type: DRUG

Ritonavir (RTV) low

Intervention Type: DRUG

Norvir®

Zidovudine

Intervention Type: DRUG

TPV/RTV high + ZDV

Group Type: EXPERIMENTAL

Tipranavir (TPV) high

Intervention Type: DRUG

Retrovir®

Ritonavir (RTV) high

Intervention Type: DRUG

Zidovudine

Intervention Type: DRUG

Interventions

Tipranavir (TPV) low

Intervention Type: DRUG

Ritonavir (RTV) low

Norvir®

Intervention Type: DRUG

Tipranavir (TPV) high

Retrovir®

Intervention Type: DRUG

Ritonavir (RTV) high

Intervention Type: DRUG

Zidovudine

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Ability and willingness to give written informed consent in accordance with institutional and federal guidelines and to comply with the investigational nature of the study and the related requirements
• Healthy males or females between 18 and 60 years of age inclusive
• A Body Mass Index between 18 and 35 kg/m2
• Ability to swallow numerous large capsules without difficulty
• Reasonable probability for completion of the study, in the opinion of the investigator
• Acceptable laboratory values that indicate adequate baseline organ function are required at the time of screening. Laboratory values are considered to be acceptable if severity <= Grade 1 based on the ACTG DAIDS Grading Scale. All abnormal laboratory values > Grade 1 (e.g., CPK, amylase, triglycerides) are subject to approval by the BIPI clinical monitor
• Acceptable medical history, physical examination, ECG, and Chest X-ray are required prior to entering the study
• Willingness to abstain from alcohol for 48 hours prior to Study Day 0 and abstain from alcohol for the duration of the study. In addition, Cabernet Sauvignon must not have been ingested within 15 days prior to Day 0 (Visit 2)
• Willingness to abstain from ingesting grapefruit and grapefruit juice within 15 days of Day 0, Visit 2 and for the duration of the study
• Willingness to abstain from ingesting Seville oranges, garlic supplements, St. John's Wort, Milk Thistle, or methylxanthine-containing drinks or food (coffee, tea, cola, energy drinks, chocolate, etc.) within 72 hours of PK sampling days (Day 1 (Visit 3), Days 11-14 (Visits 5-8))
• Willingness to abstain from use of tobacco products for the duration of the study
• Urine drug screen negative for illegal non-prescription drugs
• Negative HIV serology
• Negative for Hepatitis B surface antigen and Hepatitis C

Exclusion Criteria

• Female subjects who are of reproductive potential who:

• Have a positive serum B-HCG at Visit 1 or 2 or,
• Have not been using a barrier contraceptive method for at least 3 months prior to Visit 3 (Day 1) or,
• Are not willing to use a reliable method of double-barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam) during the trial and 30 days after completion / termination or,
• Are breast-feeding
• Participation in another trial with an investigational medicine for 30 days prior to Day 0 (Visit 2)
• Ingestion of any known enzyme altering drug (such as phenothiazines, cimetidine, barbiturates, ketoconazole, fluconazole, rifampin, steroids, and herbal medications for 30 days prior to Day 0 (Visit 2)
• Ingestion of grapefruit, grapefruit juice, and Cabernet Sauvignon within 15 days prior to Day 0 (Visit 2)
• Ingestion of Seville oranges, garlic supplements, St. John's Wort, Milk Thistle, or methylxanthine-containing drinks or food (coffee, tea, cola, energy drinks, chocolate, etc.) within 72 hours of PK sampling days [Day 1 (Visit 3), Days 11-14 (Visits 5-8)]
• Ingestion of antibiotics within 10 days prior to Day 0 (Visit 2)
• Inability to comply with investigator's instructions
• History of gastrointestinal, hepatic, or renal disorders within 60 days
• History of alcohol abuse
• Current use of cigarettes defined as greater than 10 cigarettes per day
• Blood or plasma donations within 30 days prior to Day 0 (Visit 2)
• Subjects with a seated systolic blood pressure either <100 mm Hg or >150 mm Hg; resting heart rate either <50 beats/min or >90 beats/min
• Subjects with a history of any illness or allergy that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering tipranavir or ritonavir or zidovudine to the subject
• Subjects who have had an acute illness within 2 weeks prior to Day 0 (Visit 2)
• Subjects who are currently taking any over-the-counter drug within 7 days prior to Day 0, (Visit 2) or who are currently taking any prescription drug that, in the opinion of the investigator in consultation with the BIPI clinical monitor and pharmacokineticist, might interfere with either the absorption, distribution or metabolism of the test substances
• Hypersensitivity to tipranavir, ritonavir, or zidovudine

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Boehringer Ingelheim

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

1182.37

Identifier Type: -

Identifier Source: org_study_id